The increase in Life Sciences venture capital funding in Europe continues

Venture capital funding in the European Life Sciences industry in the 1st quarter of 2021 remains unaffected by the negative impact of the COVID-19 pandemic. Compared to the 1st quarter of the previous year, accumulated Life Sciences venture capital funding in Europe has increased by 17%, reaching EUR 2,344 million so far (EUR 2,011m in Q1 2020). 76% of the accumulated funding volume was allocated to European Biotech companies (56% in Q1 2020).

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here:

[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]